Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Measles is a highly infectious viral disease which can lead to serious complications. In high income regions of the world such as Western Europe, it causes death in at least 1 in 5000 cases, but as many as 1 in 100 will die in the poorest regions of the world.

Worldwide, measles is still a major cause of death, especially among children in resource-poor countries. In 2011, 158,000 people died of measles – an average of 432 every day. However, over the last twenty years vaccination has dramatically reduced the number of deaths from measles. Since 1990 (when measles killed 872,000 people), over one in 5 of all child deaths averted have been due to measles vaccination.

In the short film below, experts talk about measles and its complications, and the importance of the MMR vaccine.

Read more about the symptoms, how it is passed on and how the MMR vaccine protects people on the Vaccine Knowledge Project website.

Similar stories

It’s not just Covid: the triple threat that could overwhelm the NHS this winter - Andrew Pollard

A severe flu outbreak or new coronavirus variant could prove catastrophic for a health service already on its knees

Novel all-in-one vaccine developed to tackle future coronavirus threats

Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.

Oral paratyphoid vaccine to begin human trials

The University of Oxford in collaboration with the University of Maryland School of Medicine (UMSoM) has begun recruiting for a Phase I/II trial of a new paratyphoid vaccine in human volunteers in Oxford.

Oxford scientist named Australian of the Year in the UK

The Oxford Vaccine Group’s Lead Statistician, Professor Merryn Voysey, received the prestigious Australian of the Year in the UK award at a gala dinner recently.

Oxford to work with Brazil to establish clinical research hub

The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.